Significant Effect of Ritodrine Hydrochloride Combined with Magnesium Sulfate for Treatment of Patients with Premature Rupture of Membranes

To investigate the effect of magnesium sulfate combined with ritodrine hydrochloride on maternal and infant outcomes in patients with premature rupture of membranes (PROM), a total of 76 PROM patients admitted to our hospital from July 2021 to July 2022 were selected as the research objects, and they were divided into observation group and experimental group according to the treatment methods of the patients. The observation group consisted of 38 patients who received magnesium sulfate monotherapy, whereas the experimental group received ritodrine hydrochloride in addition to the treatment received by the patients in the observation group. The treatment effects, levels of inflammatory factors, negative emotions, as well as maternal and child outcomes, along with any adverse reactions during the medication, were compared between the two groups. The effective rate of treatment in the observation group was 78.95%, and that in the experimental group was 97.37%. The effective rate in the experimental group was significantly higher than that in the observation group (P < 0.05). The levels of α and IFN-y were significantly lower than those of the observation group (all, P < 0.05); the SAS scores and SDS scores of the experimental group after treatment were significantly lower than those of the observation group (all, P < 0.05). The observation group showed significantly lower uterine contraction inhibition time and postpartum hemorrhage compared to the observation group, along with significantly higher gestational age extension time (all, P <0.05). In terms of neonatal outcomes, the birth weight, Apgar. The scores were significantly higher than those of the observation group, and the incidence of complications was significantly lower than that of the observation group (all, P < 0.05). The incidence of adverse reactions in the observation group was 21.05%, compared to 23.68% in the experimental group. There was no significant difference in the incidence of adverse reactions between the two groups of patients (P > 0.05). Magnesium sulfate combined with ritodrine hydrochloride has a significant effect in the treatment of patients with PROM. The application of the combined program can effectively reduce the inflammatory response of patients, regulate the negative emotions of patients, and improve the maternal and infant outcomes of patients. Moreover, the combined program does not increase the risk of adverse reactions in patients, demonstrating its ideal safety in clinical medication.